Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 11:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2905–2928 of 4,253 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Study Product Clear all

Conditions: Plantar Fasciitis
Interventions: transdermal CBD cream (Tolcylen®, Marlinz Pharma), Matched Placebos; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Anthocyanins
Interventions: ACRB, Placebo; Dietary Supplement · Other
Lead sponsor: Pharmanex; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Davis, California

Conditions: Hypertensive Renal Disease
Interventions: USUAL - take your BP Meds as you usually do, HS DOSING, ADD On Dosing; Behavioral · Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 12 more

Conditions: Stress
Interventions: Placebo Control Form 1, Relaxation Active Study Product 1.1, Placebo Control Form 2, Relaxation Active Study Product 2.1, Placebo Control Form 3, Relaxation Active Study Product 3.1, Placebo Control Form 4, Relaxation Active Study Product 4.1, Relaxation Active Study Product 4.2; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 21 Years to 105 Years
Enrollment: 1,700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Bacterial Vaginosis
Interventions: LACTIN-V, Placebo control substance; Drug
Lead sponsor: Osel, Inc.; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hysterectomy, Blood Loss, Surgical
Interventions: Tranexamic Acid, Sodium Chloride; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Endometriosis Related Pain
Interventions: Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 623 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 41
States / cities: Andalusia, Alabama • Washington D.C., District of Columbia • Aventura, Florida + 36 more

Conditions: Opiate Addiction
Interventions: Cannabidiol 400, Cannabidiol 800, Control; Drug
Lead sponsor: Hurd,Yasmin, Ph.D.; Individual
Eligibility: 21 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Traumatic Brain Injury
Interventions: Blood/saliva sampling; Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 70 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Norovirus
Interventions: CDI-988, Placebo, Snow Mountain Virus; Drug · Other
Lead sponsor: Cocrystal Pharma, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: End Stage Renal Disease, Chronic Kidney Disease Stage 5, ESRD
Interventions: AZD1722 (in-patient), Placebo (in-patient), AZD1722 (out-patient), Placebo; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 3
States / cities: Tempe, Arizona • Denver, Colorado • Minneapolis, Minnesota

Conditions: Hip Fractures, Intertrochanteric Fractures
Interventions: Tranexamic Acid (TXA), Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Gastric Cancer
Interventions: Rilotumumab, Placebo, Epirubicin, Cisplatin, Capecitabine; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 16
States / cities: Tucson, Arizona • Aurora, Colorado • Pueblo, Colorado + 13 more

Conditions: Partial Onset Seizures
Interventions: BGG492; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 66 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Tallahassee, Florida • Hamilton, New Jersey • Dallas, Texas

Conditions: Clostridium Difficile
Interventions: Misoprostol 100Mcg Tab, Placebo; Drug · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 3
States / cities: St Louis, Missouri • Chapel Hill, North Carolina • Nashville, Tennessee

Conditions: Human Papilloma Virus (HPV), High-risk Human Papillomavirus Infection
Interventions: Lopinavir / ritonavir; Drug
Lead sponsor: Daré Bioscience, Inc.; Industry
Eligibility: 22 Years to 50 Years · Female only
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 11
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 8 more

Conditions: Parkinson Disease
Interventions: HBI-002, Vehicle (placebo); Drug
Lead sponsor: Hillhurst Biopharmaceuticals, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 8
States / cities: Fountain Valley, California • Gainesville, Florida • Boston, Massachusetts + 5 more

Conditions: Hyperkalemia
Interventions: Patiromer Powder for Oral Suspension [Veltassa], Placebo; Drug
Lead sponsor: Comprehensive Research Associates; Industry
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 19
States / cities: Stanford, California • New Haven, Connecticut • Newark, Delaware + 13 more

Conditions: Healthy, Cognitive Function
Interventions: Qualia Mind, Placebo; Dietary Supplement
Lead sponsor: Neurohacker Collective; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Type 2 Diabetes Mellitus
Interventions: rosiglitazone, glyburide; Drug
Lead sponsor: University of Washington; Other
Eligibility: 35 Years to 69 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2008
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Alzheimer's Disease
Interventions: Bryostatin 1, Placebo; Drug · Other
Lead sponsor: Neurotrope Bioscience, Inc.; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 29
States / cities: Phoenix, Arizona • Costa Mesa, California • Los Alamitos, California + 26 more

Conditions: Severe Depression, Moderate Depression, Ketamine, Midazolam, Peripheral Nervous System Agents, Central Nervous System Agents, Neurotransmitter Agents, Physiologic Effects of Drugs, Sensory System Agents, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-Steroidal, Depressive Symptom, Hypnotics and Sedatives, Anti-anxiety Agents, Tranquilizing Agents, Psychotropic Drugs, Anesthetics Agent
Interventions: nebulized ketamine, nebulized midazolam; Drug
Lead sponsor: Theresa Jacob, PhD, MPH; Other
Eligibility: 18 Years to 88 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Fragile X Syndrome
Interventions: zatolmilast, Placebo; Drug
Lead sponsor: Tetra Discovery Partners; Industry
Eligibility: 9 Years to 18 Years · Male only
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 17
States / cities: Irvine, California • Orange, California • Sacramento, California + 14 more

Conditions: Sleep, Sleep Disturbance, Sleep Disorder
Interventions: Rest Study Active Product 1.1 Usage, Rest Study Active Product 1.2 Usage, Rest Study Active Product 2.1 Usage, Rest Study Active Product 2.2 Usage, Placebo Control Form 1, Placebo Control Form 2, Placebo Control Form 3, Rest Study Active Product 3.1 Usage, Placebo Control Form 4, Rest Study Active Product 4.1 Usage, Rest Study Active Product 4.2 Usage, Rest Study Active Product 4.3 Usage; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 21 Years to 105 Years
Enrollment: 4,152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Del Mar, California

Search by objective public record fields.

A Double-Blinded Study on Rapid and Sustained Pain Relief Topical Cannabidiol for Plantar Fasciitis

Inflammatory and Metabolic Responses to Long-term Dietary Supplementation With Anthocyanin-rich Blend

African American Study of Kidney Disease and Hypertension ABPM Pilot Study

Radicle Relaxation 24: A Study of Health and Wellness Products on Stress and Related Health Outcomes

Safety and Efficacy Study of Lactobacillus Administered Vaginally in Women With Bacterial Vaginosis

IV Tranexamic Acid Prior to Hysterectomy

SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

Acute and Short-term Effects of Cannabidiol Admin on Cue-induced Craving in Drug-abstinent Heroin Dependent Humans

A Pilot Study to Identify Biomarkers Associated With Chronic Traumatic Brain Injury

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Healthy Adults After Challenge With Snow Mountain Virus

Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis

Does Early Administration of Tranexamic Acid Reduce Blood Loss and Perioperative Transfusion Requirement

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Phase II BGG492 Capsule Extension for Partial Epilepsy

PROCLAIM -- Misoprostol in the Prevention of Recurrent CDI Prevent Recurrence of Clostridium Difficile Infection With Misoprostol

A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)

Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease

Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management

Safety and Efficacy Study of Qualia Mind on Cognition in a Healthy Population

Preferred Treatment of Type 1.5 Diabetes

A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease

Nebulized Ketamine for the Treatment of Major Depressive Disorder

A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome

Radicle Rest 2: A Study of Health and Wellness Products on Sleep and Health Outcomes